1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
AL Amyloidosis – Epidemiology Forecast—2030

AL Amyloidosis – Epidemiology Forecast—2030

  • December 2020
  • 89 pages
  • ID: 5993615
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘AL Amyloidosis – Epidemiology Forecast—2030’ report delivers an in-depth understanding of the AL Amyloidosis, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

AL Amyloidosis Disease Understanding
Amyloidosis refers to a group of complex diseases caused by protein misfolding and aggregation into highly ordered amyloid fibrils that deposit in tissues, resulting in progressive organ damage. A cross-?-sheet quaternary structure characterizes these amyloid fibrils. It is typically found in individuals with monoclonal gammopathy.
AL amyloidosis is characterized by the proliferation of clonal plasma cells. It causes the increased production of immunoglobulin light chains to become misfolded and aggregate into amyloid fibrils, leading to organ damage. As the amyloid builds up in an organ, nerve, or tissue, it gradually causes damage and affects their function. Each amyloidosis patient has a different pattern of amyloid deposition in their body. It often affects more than one organ, except the brain.

AL Amyloidosis Epidemiology
The AL amyloidosis epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the Incident patient pool and their trends along with assumptions undertaken.

Key Findings
The total Incident cases of AL Amyloidosis patients in the 7MM will rise during the study period, i.e., 2017–2030.
The disease epidemiology covered in the report provides historical and forecasted AL amyloidosis symptoms epidemiology segmented as the total incident cases of AL amyloidosis, Gender-specific cases of AL amyloidosis, and age-specific cases of AL amyloidosis. The report presents the incident scenario of AL amyloidosis symptoms in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
Country-wise Epidemiology of AL Amyloidosis
The epidemiology segment also provides the AL Amyloidosis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total Incident cases of AL Amyloidosis associated in 7MM countries were 8,550 in 2017.
• As per the estimates, the United States has the largest incident population of AL amyloidosis.
• In 2017, among the EU5 countries, Germany had the highest Incident cases of AL amyloidosis, followed by France. On the other hand, Spain had the lowest Incident cases, with 406 cases.

Scope of the Report
• The AL amyloidosis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• The AL amyloidosis Epidemiology Report and Model provide an overview of the risk factors and global trends of AL Amyloidosis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report provides insight into the historical and forecasted AL amyloidosis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of AL amyloidosis.
• The report provides the AL amyloidosis epidemiology segmentation by incident cases of AL amyloidosis in the 7MM.
• The report provides the AL amyloidosis epidemiology segmentation by gender-specific incident cases of AL amyloidosis in the 7MM.
• The report provides the AL amyloidosis epidemiology segmentation by age-specific incident Cases of AL Amyloidosis in the 7MM.

Report Highlights

• 11-year Forecast of AL Amyloidosis epidemiology
• 7MM Coverage
• Total Incident Cases of AL amyloidosis
• Incident Cases according to segmentation: Gender-specific cases of AL Amyloidosis
• Incident Cases according to segmentation: Age-specific cases of AL Amyloidosis

KOL- Views
We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM for the patient population of AL amyloidosis?
• What are the key findings of the AL amyloidosis epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2017–2030)?
• What would be the total number of AL amyloidosis patients across the 7MM during the forecast period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?
• What are the disease risk, burden, and unmet needs of the AL Amyloidosis?
• What are the currently available treatments of AL Amyloidosis?

Reasons to buy
The AL Amyloidosis epidemiology report will allow the user to:
• Develop business strategies by understanding the trends shaping and driving the global AL Amyloidosis market
• Quantify patient populations in the global AL Amyloidosis market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AL Amyloidosis therapeutics in each of the markets covered
• Understand the magnitude of AL amyloidosis population by its incident cases
• Understand the magnitude of AL amyloidosis population by its gender-specific cases
• Understand the magnitude of AL amyloidosis population by its age-specific cases
• The AL amyloidosis epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
• The AL amyloidosis Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2030
The unique, comprehensive medical data source available for the population of Olmsted County, Minnesota, has been of great value in determining incidence trends and prevalence rates for various diseases. Given the paucity of epidemiologic studies in AL amyloidosis, the data from the Olmsted, the country was compared throughout 1950–1989.
Kyle et al. (1992.) determined the incidence and natural history of primary systemic amyloidosis. The data from the records of all residents of Olmsted County were used, wherein a diagnosis of amyloidosis was obtained from the Mayo Clinic and its affiliated hospitals and other medical groups that might have seen local patients for the period January 1950 to December 1989. A total of 21 patients fulfilled the criteria for the diagnosis of AL; the median age was 73.5 years; 62% were men. Congestive heart failure was present in 33%, nephrotic syndrome, macroglossia 19%, carpal tunnel syndrome, hepatomegaly, renal failure (10%), and orthostatic hypotension, intermittent claudication, cardiac arrhythmia, pseudo-obstruction of the small bowel, and marked weight loss. The rectal biopsy was positive in 67%, and a bone marrow biopsy was positive in 42%. The median duration of survival from diagnosis was 2.3 years.
The age-adjusted rates were significantly greater in men than women. The age- and sex-adjusted rates were 3.9, 7.6, 5.9, and 14.4 per million person-years for the four decades from 1950 through 1989. The age-specific incidence rates increased in each decade of life after age 40 years in both men and women, except for a non-significant decrease after the eighth decade in women. No patients were younger than 40 years. The age-wise data was reported as 3.0 7.6, 15.4, 64.6, 113 for 40–49, 50–59, 60–69, 70–79, and more than 80. The overall sex- and age-adjusted rate per million person-years was 6.1 from 1950 to 1969 and 10.5 from 1970 to 1989. The similarity of these rates suggests no significant increase over time. It is the most comprehensive epidemiological study to date, and the overall age- and sex-adjusted annual rate per million person-years was 8.9 for the general population.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Chronic Kidney Disease (CKD) induced Hyperparathyroidism (HPT), Hyperphosphatemia (HP), and Hyperkalemia (HK) - Epidemiology Forecast to 2030

  • $ 3995
  • April 2021
  • 48 pages

Chronic Kidney Disease (CKD) induced Hyperparathyroidism (HPT), Hyperphosphatemia (HP), and Hyperkalemia (HK) - Epidemiology Forecast to 2030 Summary Chronic kidney disease (CKD), or chronic renal ...

  • United States
  • Italy
  • Endocrine Disease
  • Industry analysis
  • Prescription Drug Sales
  • Anemia Prevalence

ref:plp2020

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on